Molnupiravir 200 mg Capsule

Molnupiravir 200 mg Product Introduction

Molnupiravir 200 mg Capsule is the first oral antiviral medication to treat mild to moderate COVID-19 in adults. It stops the virus from multiplying, reducing viral load and disease severity. On December 28, 2021, Indian drug authorities granted it emergency use approval.

Doctors prescribe it for patients with mild to moderate COVID-19 who are at high risk of developing severe symptoms. These risk factors include obesity, age above 60, diabetes, and heart disease. It is not intended for patients needing immediate hospitalization. Both the U.S. FDA and UK regulatory agency have approved it for emergency use.

Uses

• Treatment of mild to moderate Coronavirus disease (COVID-19)

Benefits

In Treatment of Mild to Moderate Coronavirus Disease (COVID-19)

It helps manage mild to moderate COVID-19 symptoms in high-risk individuals who don’t require oxygen. If diagnosed early, this medication can aid in recovery and prevent the need for hospitalization. Consult your doctor immediately if you suspect contact with an infected person or experience symptoms.

Side Effects

Most side effects do not require medical attention and resolve as your body adjusts. Consult your doctor if they persist or cause concern.

Common Side Effects

• Nausea
• Dizziness
• Diarrhea

How to Use

Take it as prescribed by your doctor. You may take it with or without food, but taking it at the same time daily is recommended.

How it Works

It is an antiviral that inhibits the replication of the SARS-CoV-2 virus. By preventing the virus from making new copies, it lowers the viral load in the body, helping to reduce the severity of the infection.